中国医药科学2024，Vol.14Issue(5)：46-49,4.DOI:10.20116/j.issn2095-0616.2024.05.10
基于伏诺拉生方案根除幽门螺杆菌的研究进展
Research progress on the eradication of Helicobacter pylori based on the Vonoprazan regimen
摘要
Abstract
Vonoprazan(VPZ)is a new type of acid-suppressing drug,with a strong and long-lasting acid inhibitory effect,superior to traditional proton pump inhibitors(PPI),and can be widely used in acid-related diseases.Currently,its main indication in China is reflux esophagitis.More and more studies have found that compared to PPI-based regimens for eradicating Helicobacter pylori(Hp),the regimen based on VPZ can improve the success rate of Hp eradication,and the adverse reactions are equivalent or even fewer.The latest domestic guidelines for the treatment of Helicobacter pylori also mention the use of VPZ,but the usage is not clear.This article summarizes the mechanism of action,usage regimen,efficacy,and safety of VPZ in the treatment of Hp infection,aiming to provide a reference for exploring the use of VPZ in the treatment of Hp infection.关键词
伏诺拉生/幽门螺杆菌/质子泵抑制剂/疗效/安全性Key words
Vonoprazan/Helicobacter pylori/Proton pump inhibitors/Efficacy/Safety分类
医药卫生引用本文复制引用
刘涛,郑盛,杨涓..基于伏诺拉生方案根除幽门螺杆菌的研究进展[J].中国医药科学,2024,14(5):46-49,4.基金项目
云南省科技厅科技计划项目(2018FH001-076 （）
2018FH001-080). （）
